EUVIMEDEUVIMED entdecken
Crossref

PGK1 Drives Cardiac Hypertrophy by Regulating the Vimentin/PI3K/Akt Pathway

Xue-Xue Zhu, Ao-Yuan Zhang, Gui-Wen Xu, Rui Li, Sheng-Qi Gao, Le-Ming Ji, Yi-Fei Li, Ting He, Min Wei, Le Yang iD, Chen-Yang Zhao, Bernd Nürnberg iD und 5 weitere

Circulation Research · 27.03.2026 · 138 (7)

DOI: 10.1161/circresaha.125.327173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Research, erschienen am 27.03.2026. Verfasst von Xue-Xue Zhu und 16 weiteren Autor:innen. Beteiligte Einrichtung: MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases (X.-X.Z., A.-Y.Z., G.-W.X., S.-Q.G., L.-M.J., Y.-F.L., T.H., M.W…. Hauptthemen laut MEDLINE: Phosphoglycerate Kinase, Proto-Oncogene Proteins c-akt, Myocytes, Cardiac, Cardiomegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pathological cardiac hypertrophy is a major risk factor for heart failure. PGK1 (phosphoglycerate kinase 1) plays an important role in cellular energy metabolism. However, the functions of PGK1 in cardiac hypertrophy remain largely unexplored. METHODS: The expression and activity of PGK1, as well as its metabolite 3-phosphoglycerate, were examined in cardiac hypertrophy patients and mice subjected to transverse aortic constriction or Ang II (angiotensin II). Liquid chromatography-tandem mass spectrometry and co-immunoprecipitation analyses were used to identify the interacting proteins of PGK1. The potential effect of a PGK1 inhibitor CBR-470-1 was examined in a murine model of cardiac hypertrophy. RESULTS: The activation and upregulation of PGK1 were observed in myocardium tissues from mice and patients with cardiac hypertrophy. Cardiomyocyte-specific PGK1-deficiency alleviated cardiac hypertrophy and dysfunction in mice. Conversely, cardiomyocyte-specific PGK1 overexpression or infusion of 3-phosphoglycerate exacerbated cardiac hypertrophy. Mechanistically, PGK1 functioned as a protein kinase to stimulate phosphorylation of vimentin (Ser83), followed by FAK (Focal Adhesion Kinase) /Src (sarcoma)-mediated phosphorylation of PI3K (Phosphoinositide 3-Kinase)/Akt (Protein Kinase B). The activated vimentin/PI3K/Akt signaling facilitated cardiomyocyte ferroptosis. Inhibition of PGK1 by CBR-470-1 prevented cardiac hypertrophy in cellular and animal models. CONCLUSIONS: Our findings highlight a critical role for PGK1 in myocardial hypertrophy, with downstream activation of the vimentin/PI3K/Akt/ferroptosis pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoglycerate KinaseProto-Oncogene Proteins c-aktMyocytes, CardiacCardiomegalyVimentinPhosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinaseAnimalsHumansSignal TransductionMiceMaleMice, Inbred C57BLMice, KnockoutPhosphorylationCells, Cultured

Stichwörter der Autor:innen

cardiomegalyferroptosishearthypertrophymyocytesphosphoglycerate kinase

Substanzen

Phosphoglycerate KinaseProto-Oncogene Proteins c-aktVimentinPgk1 protein, mousePGK1 protein, humanPhosphatidylinositol 3-KinasesPhosphatidylinositol 3-Kinase

Autor:innen und Institutionen

  • MOE Medical Basic Research Innovation Center for Gut Microbiota and Chronic Diseases (X.-X.Z., A.-Y.Z., G.-W.X., S.-Q.G., L.-M.J., Y.-F.L., T.H., M.W., L.Y., C.-Y.Z., H.-J.S.), Wuxi School of Medicine, Jiangnan Universi…
  • Department of Clinical Research Center, Jiangnan University Medical Center (Wuxi No.2 People's Hospital) (X.-X.Z., A.-Y.Z., R.L., Y.J., X.L., Z.-J.H., H.-J.S.), Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Department of Pharmacology, Experimental Therapy and Toxicology, Institute for Experimental and Clinical Pharmacology and Pharmacogenomic, Interfaculty Center of Pharmacogenomic and Drug Research, Eberhard Karls Univers…
  • State Key Laboratory of Natural Medicines, Department of Pharmacognosy, China Pharmaceutical University, Nanjing (H.-J.S.).

ORCID-Profile: Le Yang, Bernd Nürnberg, Sandra Beer-Hammer, Xing Li, Zhi-Jun Han, Hai-Jian Sun

Zitieren

APA

Zhu, X. X., Zhang, A. Y., Xu, G. W., Li, R., Gao, S. Q., Ji, L. M., Li, Y. F., He, T., Wei, M., Yang, L., Zhao, C. Y., Nürnberg, B., Beer-Hammer, S., Jin, Y., Li, X., Han, Z. J., & Sun, H. J. (2026). PGK1 Drives Cardiac Hypertrophy by Regulating the Vimentin/PI3K/Akt Pathway. Circulation Research, 138(7). https://doi.org/10.1161/circresaha.125.327173

Vancouver

Zhu XX, Zhang AY, Xu GW, Li R, Gao SQ, Ji LM, et al. PGK1 Drives Cardiac Hypertrophy by Regulating the Vimentin/PI3K/Akt Pathway. Circulation Research. 2026;138(7). doi:10.1161/circresaha.125.327173

BibTeX
@article{Zhu2026,
  author = {Zhu, Xue-Xue and Zhang, Ao-Yuan and Xu, Gui-Wen and Li, Rui and Gao, Sheng-Qi and Ji, Le-Ming and Li, Yi-Fei and He, Ting and Wei, Min and Yang, Le and Zhao, Chen-Yang and Nürnberg, Bernd and Beer-Hammer, Sandra and Jin, Yan and Li, Xing and Han, Zhi-Jun and Sun, Hai-Jian},
  title = {PGK1 Drives Cardiac Hypertrophy by Regulating the Vimentin/PI3K/Akt Pathway},
  journal = {Circulation Research},
  year = {2026},
  volume = {138},
  number = {7},
  doi = {10.1161/circresaha.125.327173}
}
Kostenlos starten →